167 related articles for article (PubMed ID: 38102209)
1. Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma.
Kato K; Sugio T; Ikeda T; Yoshitsugu K; Miyazaki K; Suzumiya J; Yamamoto G; Kim SW; Ikegame K; Uehara Y; Mori Y; Ishikawa J; Hiramoto N; Eto T; Nakazawa H; Kobayashi H; Serizawa K; Onizuka M; Fukuda T; Atsuta Y; Suzuki R
Bone Marrow Transplant; 2024 Mar; 59(3):306-314. PubMed ID: 38102209
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of clinical outcomes of allogeneic hematopoietic stem cell transplantation for relapsed/refractory peripheral T-cell lymphoma with chemoresistance].
Wang L; Li NN; Wang Z; Wu XX; Dong YJ; Fu XR; Liu Y; Hu LD; Li XF; Wang YN; Wu YM; Ren HY; Zhang MZ; Wang MH; Li YH; Liu DH; Huang WR
Zhonghua Yi Xue Za Zhi; 2019 Dec; 99(48):3786-3791. PubMed ID: 31874515
[No Abstract] [Full Text] [Related]
3. [Role and progress of allogeneic hematopoietic stem cell transplantation in the treatment of refractory/relapsed diffuse large B-cell lymphoma].
Cao LQ; Mo XD
Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):308-312. PubMed ID: 38716606
[TBL] [Abstract][Full Text] [Related]
4. The salvage role of allogeneic hematopoietic stem-cell transplantation in relapsed/refractory diffuse large B cell lymphoma.
Min GJ; Jeon YW; Kim TY; Kwag D; Kim BS; Lee J; Lee JH; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Cho SG
Sci Rep; 2023 Oct; 13(1):17496. PubMed ID: 37840059
[TBL] [Abstract][Full Text] [Related]
5. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia.
Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P
Front Immunol; 2021; 12():605766. PubMed ID: 34025637
[TBL] [Abstract][Full Text] [Related]
6. [Outcomes of 33 patients with anaplastic large cell lymphoma treated after hematopoietic stem cell transplantation].
Lu N; Li XF; Dong YJ; Wang YN; Fu XR; Wu YM; Li YH; Wang MH; Li NN; Ren HY; Wang Z; Zhang MZ; Wu XX; Hu LD; Liu Y; Huang WR
Zhonghua Xue Ye Xue Za Zhi; 2020 Feb; 41(2):117-122. PubMed ID: 32135627
[No Abstract] [Full Text] [Related]
7. Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?
Klyuchnikov E; Bacher U; Kroll T; Shea TC; Lazarus HM; Bredeson C; Fenske TS
Bone Marrow Transplant; 2014 Jan; 49(1):1-7. PubMed ID: 23708703
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation treatment for T lymphoblastic leukemia/lymphoma].
Luo L; Jiao Y; Yang P; Li Y; Huang WY; Ke XY; Zou DH; Jing HM
Zhonghua Xue Ye Xue Za Zhi; 2023 May; 44(5):388-394. PubMed ID: 37550188
[No Abstract] [Full Text] [Related]
9. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
Front Immunol; 2021; 12():755549. PubMed ID: 34777367
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors of second hematopoietic allogeneic stem cell transplantation among hematological malignancy patients relapsed after first hematopoietic stem cell transplantation: A single center study.
Lu Y; Zhang JP; Zhao YL; Xiong M; Sun RJ; Cao XY; Wei ZJ; Zhou JR; Liu DY; Yang JF; Zhang X; Lu DP; Lu P
Front Immunol; 2022; 13():1066748. PubMed ID: 36685540
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic stem cell transplantation for diffuse large B-cell lymphoma having 8q24/MYC rearrangement in Japan.
Takahashi T; Suzuki R; Yamamoto G; Nakazawa H; Kurosawa M; Kobayashi T; Okada M; Akasaka T; Kim SW; Fukuda T; Ichinohe T; Atsuta Y; Suzumiya J
Hematol Oncol; 2021 Feb; 39(1):66-74. PubMed ID: 32979280
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/ Refractory Diffuse Large B Cell Lymphoma.
Xiao Z; Li J; Miao K
Curr Stem Cell Res Ther; 2017; 12(1):14-18. PubMed ID: 27396370
[TBL] [Abstract][Full Text] [Related]
13. A multicenter retrospective study on the real-world outcomes of autologous vs. allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphoma in China.
Gu ZY; Dong YJ; Fu XR; Li NN; Liu Y; Wu XX; Wang YN; Li YH; Ren HY; Zhang MZ; Li XF; Wang MH; Wu YM; Liu DH; Wang Z; Hu LD; Huang WR
Chin Med J (Engl); 2021 Jun; 134(13):1584-1592. PubMed ID: 34133361
[TBL] [Abstract][Full Text] [Related]
14. [Clinical outcomes of hematopoietic stem cell transplantation for angioimmunoblastic T-cell lymphoma].
Xu LM; Li NN; Wang Z; Wu XX; Dong YJ; Fu XR; Liu Y; Hu LD; Li XF; Wang YN; Wu YM; Ren HY; Zhang MZ; Wang MH; Li YH; Huang WR
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):573-577. PubMed ID: 32397020
[No Abstract] [Full Text] [Related]
15. [Efficacy of CLAE Chemotherapy Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Leukemia].
Tao SD; Song LX; Deng Y; Chen Y; Zhang X; Ding BH; Wang CL; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):677-684. PubMed ID: 37356926
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Survival Between Autologous and Allogeneic Stem Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Meta-Analysis.
Wang J; Duan X; Yang L; Liu X; Hao C; Dong H; Gu H; Tang H; Dong B; Zhang T; Gao G; Liang R
Cell Transplant; 2020; 29():963689720975397. PubMed ID: 33238731
[TBL] [Abstract][Full Text] [Related]
17. [Second allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and donor changes in relapsed hematological malignancies after the first allogeneic transplant].
Zhao YQ; Song YZ; Li ZH; Yang F; Xu T; Li FF; Yang DF; Wu T
Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):465-471. PubMed ID: 37550201
[No Abstract] [Full Text] [Related]
18. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y
Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG
Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
